Alzheimer’s disease (AD) is a disorder associated with continuing deterioration of neurons in the brain and is characterised by aggregation of neurotoxic amyloid beta (Aβ) plaques. It is also accompanied by increased oxidative stress, cholinergic impairment, and remarkably reduced brain-derived neurotrophic factor (BDNF). The net result is progressive loss of memory and cognitive abilities. The study aims to explore the anti-AD profile of magnolol. AD was induced in adult Swiss albino mice by simultaneously administering aluminium chloride at a dose of 5 mg/kg/ day; p.o. and D-galactose at a dose of 60 mg/kg/day; i.p. for a period of 90 days. The dose dependent ameliorative effect of magnolol (20 and 40 mg/kg/day; p.o.) was assessed with the help of behavioural, biochemical and Enzyme- Linked Immunosorbent Assay (ELISA) analyses. Magnolol was shown to ameliorate memory and cognitive insufficiencies as assessed from Morris Water Maze, Elevated Plus Maze and Novel Object Recognition paradigms. It also elicited a remarkable antioxidant effect, as evidenced by analysing various parameters like thiobarbituric acid reactive substances, glutathione, and catalase. Magnolol also had an inhibitory activity on acetylcholinesterase, β-secretase and caspase-3. Disintegration of Aβ plaques and improvement of BDNF levels were also reported in the present study. Magnolol presents a multifactorial approach, beyond its conventional antioxidant mechanism, against experimentally induced AD in mice.
Anand A, Khurana N, Sharma N, Kumar R, Sharma D, Kumari N, Singh B. Neuroprotective effects of magnolol in aluminium chloride and D-galactose induced Alzheimer’s disease model. J Appl Pharm Sci. 2026. Article in Press. http://doi.org/10.7324/JAPS.2026.289886
1. Anand A, Khurana N, Kumar R, Sharma N. Food for the mind: the journey of probiotics from foods to anti-Alzheimer’s disease therapeutics. Food Biosci. 2023;51:102323. doi: https://doi.org/10.1016/J.FBIO.2022.102323
2. Anand A, Patience AA, Sharma N, Khurana N. The present and future of pharmacotherapy of Alzheimer’s disease: a comprehensive review. Eur J Pharmacol. 2017;815:364–75. doi: https://doi.org/10.1016/J.ejphar.2017.09.043
3. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348:1333–41. doi: https://doi.org/10.1056/NEJMoa013128
4. Anand A, Khurana P, Chawla J, Sharma N, Khurana N. Emerging treatments for the behavioral and psychological symptoms of dementia. CNS Spectr. 2017;23:361–9. doi: https://doi.org/10.1017/S1092852917000530
5. Maurer K, Ihl R, Dierks T, Frölich L. Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. J Psychiatr Res. 1997;31:645–55. doi: https://doi.org/10.1016/S0022-3956(97)00022-8
6. Saraf MK, Prabhakar S, Khanduja KL, Anand A. Bacopa monniera attenuates scopolamine-induced impairment of spatial memory in mice. Evidence-Based Complementary Alternative Med. 2011;2011:1–19. doi: https://doi.org/10.1093/ecam/neq038
7. Habtemariam S. The therapeutic potential of rosemary (Rosmarinus officinalis) diterpenes for Alzheimer’s disease. Evidence-Based Complementary Alternative Med. 2016;2016:1–4. doi: https://doi.org/10.1155/2016/2680409
8. Da Rosa MM, De Amorim LC, Alves JV de O, Aguiar IF da S, Oliveira FG da S, Da Silva MV, et al. The promising role of natural products in Alzheimer’s disease. Brain Disord. 2022;7:100049. doi: https://doi.org/10.1016/J.DSCB.2022.100049
9. Chiroma SM, Mohd Moklas MA, Mat Taib CN, Baharuldin MTH, Amon Z. D-galactose and aluminium chloride induced rat model with cognitive impairments. Biomed Pharmacother. 2018;103:1602– 8. doi: https://doi.org/10.1016/J.BIOPHA.2018.04.152
10. Li H, Zheng L, Chen C, Liu X, Zhang W. Brain senescence caused by elevated levels of reactive metabolite methylglyoxal on D-galactose-induced aging mice. Front Neurosci. 2019;13:1004. doi: https://doi.org/10.3389/FNINS.2019.01004/BIBTEX
11. Shwe T, Pratchayasakul W, Chattipakorn N, Chattipakorn SC. Role of D-galactose-induced brain aging and its potential used for therapeutic interventions. Exp Gerontol. 2018;101:13–36. doi: https://doi.org/10.1016/J.EXGER.2017.10.029
12. Haider S, Liaquat L, Ahmad S, Batool Z, Siddiqui RA, Tabassum S, et al. Naringenin protects AlCl3/D-galactose induced neurotoxicity in rat model of AD via attenuation of acetylcholinesterase levels and inhibition of oxidative stress. PLoS One. 2020;15:227631. doi: https://doi.org/10.1371/JOURNAL.PONE.0227631
13. Xing Z, He Z, Wang S, Yan Y, Zhu H, Gao Y, et al. Ameliorative effects and possible molecular mechanisms of action of fibrauretine from Fibraurea recisa Pierre on D-galactose/AlCl3-mediated Alzheimer’s disease. RSC Adv. 2018;8:31646–57. doi: https://doi.org/10.1039/C8RA05356A
14. Xiao F, Li XG, Zhang XY, Hou JD, Lin LF, Gao Q, et al. Combined administration of D-galactose and aluminium induces Alzheimer-like lesions in brain. Neurosci Bull. 2011;27:143–55. doi: https://doi.org/10.1007/s12264-011-1028-2
15. Gao L, Peng XM, Huo SX, Liu XM, Yan M. Memory enhancement of Acteoside (Verbascoside) in a senescent mice model induced by a combination of d-gal and AlCl3. Phytotherapy Res. 2015;29:1131–6. doi: https://doi.org/10.1002/ptr.5357
16. Poivre M, Duez P. Biological activity and toxicity of the Chinese herb Magnolia officinalis Rehder & E. Wilson (Houpo) and its constituents. J Zhejiang Univ Sci B. 2017;18:194. doi: https://doi.org/10.1631/JZUS.B1600299
17. Kuribara H, Kishi E, Hattori N, Okada M, Maruyama Y. The anxiolytic effect of two oriental herbal drugs in Japan attributed to honokiol from magnolia bark. J Pharm Pharmacol. 2000;52:1425–9. doi: https://doi.org/10.1211/0022357001777432
18. Iwasaki K, Wang Q, Seki H, Satoh K, Takeda A, Arai H, et al. The effects of the traditional Chinese medicine, “Banxia Houpo Tang (Hange-Koboku To)” on the swallowing reflex in Parkinson’s disease. Phytomedicine. 2000;7:259–63. doi: https://doi.org/10.1016/S0944-7113(00)80042-2
19. Koetter U, Barrett M, Lacher S, Abdelrahman A, Dolnick D. Interactions of Magnolia and Ziziphus extracts with selected central nervous system receptors. J Ethnopharmacol. 2009;124:421–5. doi: https://doi.org/10.1016/J.JEP.2009.05.040
20. Hoi CP, Ho YP, Baum L, Chow AHL. Neuroprotective effect of honokiol and magnolol, compounds from Magnolia officinalis, on beta-amyloid-induced toxicity in PC12 cells. Phytother Res. 2010;24:1538–42. doi: https://doi.org/10.1002/ptr.3178
21. Xie Z, Zhao J, Wang H, Jiang Y, Yang Q, Fu Y, et al. Magnolol alleviates Alzheimer’s disease-like pathology in transgenic C. elegans by promoting microglia phagocytosis and the degradation of beta-amyloid through activation of PPAR-γ. Biomed Pharmacother. 2020;124:109886. doi: https://doi.org/10.1016/J. BIOPHA.2020.109886
22. Anand A, Nuthan Kumar Babu V, Giriyam R, Turan S, Sharma N, Khurana N, et al. The relationship of magnolol, an important phytoconstituent, with neurological disorders: an In silico evaluation. Plant Cell Biotechnol Mol Biol. 2021;22:389–97.
23. Cheng J, Dong S, Yi L, Geng D, Liu Q. Magnolol abrogates chronic mild stress-induced depressive-like behaviors by inhibiting neuroinflammation and oxidative stress in the prefrontal cortex of mice. Int Immunopharmacol. 2018;59:61–7. doi: https://doi.org/10.1016/J.INTIMP.2018.03.031
24. Xian YF, Qu C, Liu Y, Ip SP, Yuan QJ, Yang W, et al. Magnolol ameliorates behavioral impairments and neuropathology in a transgenic mouse model of Alzheimer’s disease. Oxidative Med Cellular Longevity. 2020;2020:5920476. doi: https://doi.org/10.1155/2020/5920476
25. Itoh J, Nabeshima T, Kameyama T. Utility of an elevated plus-maze for the evaluation of memory in mice: effects of nootropics, scopolamine and electroconvulsive shock. Psychopharmacology (Berl). 1990;101:27–33. doi: https://doi.org/10.1007/BF02253713
26. Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc. 2006;1:848–58. doi: https://doi.org/10.1038/nprot.2006.116
27. Bromley -Brits K, Deng Y, Song W. Morris Water Maze test for learning and memory deficits in Alzheimer’s disease model mice. J Visualized Experiments. 2011; 13: e2920. doi: https://doi.org/10.3791/2920
28. Antunes M, Biala G. The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn Process. 2012;13:93–110. doi: https://doi.org/10.1007/s10339-011-0430-z
29. Lueptow LM. Novel object recognition test for the investigation of learning and memory in mice. J Visualized Experiments. 2017;2017:55718. doi: https://doi.org/10.3791/55718
30. Anand A, Khurana N, Ali N, AlAsmari AF, Alharbi M, Waseem M, et al. Ameliorative effect of vanillin on scopolamine-induced dementia-like cognitive impairment in a mouse model. Front Neurosci. 2022;0:1748. doi: https://doi.org/10.3389/FNINS.2022.1005972
31. Habibyar AF, Sharma N, Khurana N. PASS assisted prediction and pharmacological evaluation of hesperidin against scopolamine induced amnesia in mice. Eur J Pharmacol. 2016;789:385–94. doi: https://doi.org/10.1016/J.ejphar.2016.07.013
32. Anand A, Khurana N, Kaur S, Ali N, Alasmari AF, Waseem M, et al. The multifactorial role of vanillin in amelioration of aluminium chloride and D-galactose induced Alzheimer’s disease in mice. Eur J Pharmacol. 2023;954:175832. doi: https://doi.org/10.1016/J. EJPHAR.2023.175832
33. Su D, Zhao Y, Wang B, Xu H, Li W, Chen J, et al. Isoflurane-induced spatial memory impairment in mice is prevented by the acetylcholinesterase inhibitor donepezil. PLoS One. 2011;6:e27632. doi: https://doi.org/10.1371/JOURNAL.PONE.0027632
34. Gao J, He H, Jiang W, Chang X, Zhu L, Luo F, et al. Salidroside ameliorates cognitive impairment in a d-galactose-induced rat model of Alzheimer’s disease. Behavioural Brain Res. 2015;293:27–33. doi: https://doi.org/10.1016/J.BBR.2015.06.045
35. Kawahara M, Kato-Negishi M. Link between Aluminum and the pathogenesis of Alzheimer’s disease: the integration of the Aluminum and amyloid cascade hypotheses. Int J Alzheimers Dis. 2011;2011:276393. doi: https://doi.org/10.4061/2011/276393
36. Moumen R, Ait-Oukhatar N, Bureau F, Fleury C, Bouglé D, Arhan P, et al. Aluminium increases xanthine oxidase activity and disturbs antioxidant status in the rat. J Trace Elements Med Biol. 2001;15:89–93. doi: https://doi.org/10.1016/S0946-672X(01)80049-3
37. Platt B, Fiddler G, Riedel G, Henderson Z. Aluminium toxicity in the rat brain: histochemical and immunocytochemical evidence. Brain Res Bull. 2001;55:257–67. doi: https://doi.org/10.1016/s0361-9230(01)00511-1
38. Boni UD, Otvos A, Scott JW, Crapper DR. Neurofibrillary degeneration induced by systemic aluminum. Acta Neuropathol. 1976;35:285–94.
39. Shunan D, Yu M, Guan H, Zhou Y. Neuroprotective effect of Betalain against AlCl3-induced Alzheimer’s disease in Sprague Dawley Rats via putative modulation of oxidative stress and nuclear factor kappa B (NF-κB) signaling pathway. Biomed Pharmacother. 2021;137:111369. doi: https://doi.org/10.1016/J.BIOPHA.2021.111369
40. Skalny A, Aschner M, Jiang Y, Gluhcheva Y, Tizabi Y, Lobinski R, et al. Molecular mechanisms of aluminum neurotoxicity: update on adverse effects and therapeutic strategies. Adv Neurotoxicol. 2021:10:1–34. doi: https://doi.org/10.1016/bs.ant.2020.12.001ï
41. Mesole SB, Alfred OO, Yusuf UA, Lukubi L, Ndhlovu D. Apoptotic inducement of neuronal cells by aluminium chloride and the neuroprotective effect of Eugenol in Wistar Rats. Oxid Med Cell Longev. 2020;2020:8425643. doi: https://doi.org/10.1155/2020/8425643
42. Abbas F, Eladl MA, El-Sherbiny M, Abozied N, Nabil A, Mahmoud SM, et al. Celastrol and thymoquinone alleviate aluminum chloride-induced neurotoxicity: behavioral psychomotor performance, neurotransmitter level, oxidative-inflammatory markers, and BDNF expression in rat brain. Biomed Pharmacother. 2022;151:113072. doi: https://doi.org/10.1016/J.BIOPHA.2022.113072
43. Wei Y, Liu D, Zheng Y, Li H, Hao C, Ouyang W. Protective effects of kinetin against aluminum chloride and D-galactose induced cognitive impairment and oxidative damage in mouse. Brain Res Bull. 2017;134:262–72. doi: https://doi.org/10.1016/J.brainresbull.2017.08.014
44. Nazari QA, Kume T, Takada-Takatori Y, Izumi Y, Akaike A. Protective effect of luteolin on an oxidative-stress model induced by microinjection of sodium nitroprusside in mice. J Pharmacol Sci. 2013;122:109–17. doi: https://doi.org/10.1254/jphs.13019FP
45. Parle M, Dhingra D, Kulkarni SK. Memory-strengthening activity of Glycyrrhiza glabra in exteroceptive and interoceptive behavioral models. J Med Food. 2004;7:462–6. doi: https://doi.org/10.1089/jmf.2004.7.462
46. Leger M, Quiedeville A, Bouet V, Haelewyn B, Boulouard M, Schumann-Bard P, et al. Object recognition test in mice. Nature Protocols. 2013;8(12):2531–47. doi: https://doi.org/10.1038/nprot.2013.155
47. Morris RGM. Spatial localization does not require the presence of local cues. Learn Motiv. 1981;12:239–60. doi: https://doi.org/10.1016/0023-9690(81)90020-5
48. Vorhees CV, Williams MT. Assessing spatial learning and memory in rodents. ILAR J. 2014;55:310–2. doi: https://doi.org/10.1093/ilar/ilu013
49. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351–8. doi: https://doi.org/10.1016/0003-2697(79)90738-3
50. Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. J Lab Clin Med. 1963 ;61:882–8.
51. Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121–6. doi: https://doi.org/10.1016/S0076-6879(84)05016-3
52. Ellman GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961;7:88–95. doi: https://doi.org/10.1016/0006-2952(61)90145-9
53. Vassar R, Kovacs DM, Yan R, Wong PC. Symposium: the β-Secretase Enzyme BACE in health and Alzheimer’s disease: regulation, cell biology, function, and therapeutic potential. J Neurosci. 2009;29:12787. doi: https://doi.org/10.1523/JNEUROSCI.3657-09.2009
54. Bioassay Technology Laboratory. Protocols - BT LAB. Shanghai Korain Biotech, Shanghai, China. [cited 2022 Nov 8]. 2022. Available from: https://www.bt-laboratory.com/index.php/Shop/Index/protocols.html
55. D’Amelio M, Cavallucci V, Middei S, Marchetti C, Pacioni S, Ferri A, et al. Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer’s disease. Nature Neurosci. 2010;14(1):69–76. doi: https://doi.org/10.1038/nn.2709
56. CUSABIO. Mouse caspase 3,Casp-3 ELISA Kit – Cusabio. CUSABIO, Wuhan, China; 2022 [cited 2022 Nov 9]. Available from: https://www.cusabio.com/ELISA-Kit/Mouse-Caspase-3Casp-3-ELISA-Kit-69045.html
57. Sadigh-Eteghad S, Sabermarouf B, Majdi A, Talebi M, Farhoudi M, Mahmoudi J. Amyloid-beta: a crucial factor in Alzheimer’s disease. Med Princ Pract. 2015;24:1–10. doi: https://doi.org/10.1159/000369101
58. Anand A, Chawla J, Mahajan A, Sharma N, Khurana N. Therapeutic potential of epigallocatechin gallate. Int J Green Pharm. 2017;11:S364–70. doi: https://doi.org/10.22377/ijgp.v11i03.1143
59. CUSABIO. Mouse amyloid beta peptide 1−42 (Aβ1−42) ELISA Kit- CUSABIO CUSABIO, Wuhan, China. [cited 2022 Nov 9]. 2022. Available from: https://www.cusabio.com/ELISA-Kit/Mouse-amyloid-beta-peptide-1-42A%CE%B21-42-ELISA-Kit-66283.html
60. Giuffrida ML, Copani A, Rizzarelli E. A promising connection between BDNF and Alzheimer’s disease. Aging (Albany NY). 2018;10:1791. doi: https://doi.org/10.18632/AGING.101518
61. Bioassay Technology Laboratory. Mouse brain derived neurotrophic facor, BDNF ELISA Kit - BT LAB [cited 2022 Nov 9]. 2022. Available from: https://www.bt-laboratory.com/index.php/Shop/Index/productShijiheDetail/p_id/2202.html
62. Heneka MT, Carson MJ, Khoury J el, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14:388–405. doi: https://doi.org/10.1016/S1474-4422(15)70016-5
63. Alzheimer’s Association. What is Alzheimer’s? Alzheimer’s Association, Chicago, IL; 2017.
64. Betteridge DJ. What is oxidative stress?. Metabolism. 2000;49:3–8. doi: https://doi.org/10.1016/s0026-0495(00)80077-3
65. Huang WJ, Zhang X, Chen WW. Role of oxidative stress in Alzheimer’s disease. Biomed Rep. 2016;4:519–22. doi: https://doi.org/10.3892/br.2016.630
66. Chauhan P, Vadia N, Ballal S, Joshi KK, Maharana L, Chauhan AS, et al. Decoding the neuroprotective potential of hesperidin: insights into Alzheimer’s disease. Neuroscience. 2025;589:205–20. doi: https://doi.org/10.1016/J.NEUROSCIENCE.2025.09.028
67. Song S, Ma X, Zhou Y, Xu M, Shuang S, Dong C. Studies on the interaction between vanillin and β-Amyloid protein via fluorescence spectroscopy and atomic force microscopy. Chem Res Chin Univ. 2016;32:172–7. doi: https://doi.org/10.1007/s40242-016-5347-8
68. He M, Zhao L, Wei MJ, Yao WF, Zhao HS, Chen FJ. Neuroprotective effects of (−)-epigallocatechin-3-gallate on aging mice induced by D-galactose. Biol Pharm Bull. 2009;32:55–60. doi: https://doi.org/10.1248/BPB.32.55
69. Singh NA, Bhardwaj V, Ravi C, Ramesh N, Mandal AKA, Khan ZA. EGCG nanoparticles attenuate aluminum chloride induced neurobehavioral deficits, beta amyloid and Tau Pathology in a rat model of Alzheimer’s disease. Front Aging Neurosci. 2018;10:244. doi: https://doi.org/10.3389/FNAGI.2018.00244
70. Amorati R, Zotova J, Baschieri A, Valgimigli L. Antioxidant activity of magnolol and Honokiol: kinetic and mechanistic investigations of their reaction with peroxyl radicals. J Organic Chem. 2015;80:10651–9. doi: https://doi.org/10.1021/ACS.JOC.5B01772
71. Shen JL, Man KM, Huang PH, Chen WC, Chen DC, Cheng YW, et al. Honokiol and magnolol as multifunctional antioxidative molecules for dermatologic disorders. Molecules. 2010;15:6452. doi: https://doi.org/10.3390/MOLECULES15096452
72. Lee YK, Yuk DY, Kim TI, Kim YH, Kim KT, Kim KH, et al. Protective effect of the ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity. J Natural Med. 2009;63(3):274–82. doi: https://doi.org/10.1007/S11418-009-0330-Z
73. Hou YC, Lee Chao PD, Chen SY. Honokiol and magnolol increased hippocampal acetylcholine release in freely-moving rats. Am J Chin Med (Gard City N Y). 2000;28:379–84. doi: https://doi.org/10.1142/S0192415X00000441
74. Santos J, Quimque MT, Liman RA, Agbay JC, Macabeo APG, Corpuz MJA, et al. Computational and experimental assessments of magnolol as a neuroprotective agent and utilization of UiO-66(Zr) as its drug delivery system. ACS Omega. 2021;6:24382. doi: https://doi.org/10.1021/ACSOMEGA.1C02555
75. Liu Z, Xie J, Lin K, Qi L. Influencing mechanism of magnolol on expression of BDNF and Bax in rats with cerebral ischemic stroke. Exp Ther Med. 2018;16:4423. doi: https://doi.org/10.3892/ETM.2018.6807
76. Li LF, Lu J, Li XM, Xu CL, Deng JM, Qu R, et al. Antidepressant-like effect of magnolol on BDNF up-regulation and serotonergic system activity in unpredictable chronic mild stress treated rats. Phytother Res. 2012;26:1189–94. doi: https://doi.org/10.1002/PTR.3706
77. Zhu S, Liu F, Zhang R, Xiong Z, Zhang Q, Hao L, et al. Neuroprotective potency of neolignans in Magnolia officinalis cortex against brain disorders. Front Pharmacol. 2022;13:857449. doi: https://doi.org/10.3389/fphar.2022.857449
78. Li H, Liu X, Zhu Y, Liu Y, Wang Y. Magnolol derivative 002C-3 protects brain against ischemia–reperfusion injury via inhibiting apoptosis and autophagy. Neurosci Lett. 2015;588:178–83. doi: https://doi.org/10.1016/J.NEULET.2015.01.007
Year
Month